Pembrolizumab and pralatrexate for relapsed or refractory peripheral T‐cell lymphomas

The authors declare no relevant conflicts of interest. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Figure S1. Progression-free and overall survival of pralatrexate and pembrolizumab treatment. Table S1. Summary of dose-limiting toxicities (cycles 1–2). Table S2. Treatment-related adverse events (highest grade) occurring in ≥2 patients or ≥10%. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.